Cargando…

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

BACKGROUND: The treatment responses of immune checkpoint inhibitors in metastatic renal cell carcinoma (mRCC) vary, requiring reliable prognostic biomarkers. We assessed the prognostic ability of computed tomography (CT) texture analysis in patients with mRCC treated with programmed death receptor-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyo Jung, Qin, Lei, Bakouny, Ziad, Krajewski, Katherine M, Van Allen, Eliezer M, Choueiri, Toni K, Shinagare, Atul B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074990/
https://www.ncbi.nlm.nih.gov/pubmed/35348767
http://dx.doi.org/10.1093/oncolo/oyac034
_version_ 1784701581693812736
author Park, Hyo Jung
Qin, Lei
Bakouny, Ziad
Krajewski, Katherine M
Van Allen, Eliezer M
Choueiri, Toni K
Shinagare, Atul B
author_facet Park, Hyo Jung
Qin, Lei
Bakouny, Ziad
Krajewski, Katherine M
Van Allen, Eliezer M
Choueiri, Toni K
Shinagare, Atul B
author_sort Park, Hyo Jung
collection PubMed
description BACKGROUND: The treatment responses of immune checkpoint inhibitors in metastatic renal cell carcinoma (mRCC) vary, requiring reliable prognostic biomarkers. We assessed the prognostic ability of computed tomography (CT) texture analysis in patients with mRCC treated with programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. MATERIALS AND METHODS: Sixty-eight patients with mRCC treated with PD-1/PD-L1 inhibitors between 2012 and 2019 were revaluated. Using baseline and first follow-up CT, baseline and follow-up texture models were developed to predict overall survival (OS) and progression-free survival (PFS) using least absolute shrinkage and selection operator Cox-proportional hazards analysis. Patients were divided into high-risk or low-risk group, and the survival difference was assessed using Kaplan-Meier and log-rank test. Multivariable Cox models were constructed by including only the clinical variables (clinical models) and by combining the clinical variables and the texture models (combined clinical-texture models), and their predictive performance was evaluated using Harrell’s C-index. RESULTS: The baseline texture models distinguished longer- and shorter-term survivors for both OS (median, 60.1 vs. 17.0 months; P = .048) and PFS (5.2 vs. 2.8 months; P = .003). The follow-up texture models distinguished longer- and shorter-term overall survivors (40.3 vs. 15.2 months; P = .008) but not for PFS (5.0 vs. 3.6 months; P = .25). The combined clinical-texture model outperformed the clinical model in both predicting the OS (C-index, 0.70 vs. 0.63; P = .03) and PFS (C-index, 0.63 vs. 0.55; P = .04). CONCLUSION: CT texture analysis performed at baseline and early after starting PD-1/PD-L1 inhibitors is associated with clinical outcomes of patients with mRCC.
format Online
Article
Text
id pubmed-9074990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90749902022-05-09 Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Park, Hyo Jung Qin, Lei Bakouny, Ziad Krajewski, Katherine M Van Allen, Eliezer M Choueiri, Toni K Shinagare, Atul B Oncologist Genitourinary Cancer BACKGROUND: The treatment responses of immune checkpoint inhibitors in metastatic renal cell carcinoma (mRCC) vary, requiring reliable prognostic biomarkers. We assessed the prognostic ability of computed tomography (CT) texture analysis in patients with mRCC treated with programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors. MATERIALS AND METHODS: Sixty-eight patients with mRCC treated with PD-1/PD-L1 inhibitors between 2012 and 2019 were revaluated. Using baseline and first follow-up CT, baseline and follow-up texture models were developed to predict overall survival (OS) and progression-free survival (PFS) using least absolute shrinkage and selection operator Cox-proportional hazards analysis. Patients were divided into high-risk or low-risk group, and the survival difference was assessed using Kaplan-Meier and log-rank test. Multivariable Cox models were constructed by including only the clinical variables (clinical models) and by combining the clinical variables and the texture models (combined clinical-texture models), and their predictive performance was evaluated using Harrell’s C-index. RESULTS: The baseline texture models distinguished longer- and shorter-term survivors for both OS (median, 60.1 vs. 17.0 months; P = .048) and PFS (5.2 vs. 2.8 months; P = .003). The follow-up texture models distinguished longer- and shorter-term overall survivors (40.3 vs. 15.2 months; P = .008) but not for PFS (5.0 vs. 3.6 months; P = .25). The combined clinical-texture model outperformed the clinical model in both predicting the OS (C-index, 0.70 vs. 0.63; P = .03) and PFS (C-index, 0.63 vs. 0.55; P = .04). CONCLUSION: CT texture analysis performed at baseline and early after starting PD-1/PD-L1 inhibitors is associated with clinical outcomes of patients with mRCC. Oxford University Press 2022-03-28 /pmc/articles/PMC9074990/ /pubmed/35348767 http://dx.doi.org/10.1093/oncolo/oyac034 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Genitourinary Cancer
Park, Hyo Jung
Qin, Lei
Bakouny, Ziad
Krajewski, Katherine M
Van Allen, Eliezer M
Choueiri, Toni K
Shinagare, Atul B
Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title_full Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title_fullStr Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title_full_unstemmed Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title_short Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
title_sort computed tomography texture analysis for predicting clinical outcomes in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
topic Genitourinary Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074990/
https://www.ncbi.nlm.nih.gov/pubmed/35348767
http://dx.doi.org/10.1093/oncolo/oyac034
work_keys_str_mv AT parkhyojung computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT qinlei computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT bakounyziad computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT krajewskikatherinem computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT vanalleneliezerm computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT choueiritonik computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors
AT shinagareatulb computedtomographytextureanalysisforpredictingclinicaloutcomesinpatientswithmetastaticrenalcellcarcinomatreatedwithimmunecheckpointinhibitors